giuseppe viscardi

MD, PhD. Lung Medical Oncologist at Monaldi Hospital in Naples. AIOM Giovani WG.
Fighting against the emperor of all maladies.

[Stephen V Liu, MD @StephenVLiu]

Great moderation at the 6th Lung Cancer Cocktail with Science held at Istituto Nazionale dei Tumori in Milano. Engaging discussion and great lectures. Congratulations to chair @GLoRussoMD_PhD.

[giuseppe viscardi @giusvisc]

#ESMO2025 sets new OS goals in driver+ #NSCLC:
47 mo with Enco+Bini in BRAF+
81 mo with Alectinib in ALK+

Understanding molecular heterogeneity & resistance mechanisms, thoughtful sequencing, QoL-focused tox control, oligoPD management to translate these results in clinics

[giuseppe viscardi @giusvisc]

At #ESMO2025 we present the INCLUDE study by @AIOMtweet Young Oncologists WG on LGBTQIA+ professionals inclusion and equity dinamics in italian oncology.

Respectful, supportive and inclusive workplaces boost well-being and quality of care! 🌈

@lorenzobellu @MOcchipintiMD

[giuseppe viscardi @giusvisc]

Generating hypothesis data from MDT-BRIDGE, but caution is needed
❗ 28% of borderline resectable unresected after CT-IO, 18% reassessed as unresectable
❓Surgery > RT if resectability achieved?
❓ CT-IO->RT = concurrent C-RT? How to adapt RT?
⚠️ Evidence still lacking
#esmo2025

[Roberto Ferrara @RobertoFerrara_]

MDT Bridge from the other side of the coin:
15% of patients and 30% of borderline resectable will never receive surgery.
Maintanance post chemo-RT in a 'PACIFIC style' could be not enough considering the previous exposure to ICI in the neoadjuvant setting
@AndrearicFili #ESMO25

[giuseppe viscardi @giusvisc]

Molecular features, tumor burden, toxicity profile and patient preferences can guide a sequencing strategy in EGFR and ALK driven NSCLC.

[Roberto Ferrara @RobertoFerrara_]

2 messages in my opinion from Alex (OS no stat sign with 47% of pts in crizo receiving ALK TKI at PD, and no data stratified for that) & Flaura2 (crossing of curves in NON-high risk pts):
- sequencing is possible (better with brain active TKIs)
- descalate is possible in low-risk

[arsela prelaj @PrelajArsela]

Amazing WCLC sharing with My dear Friends: @RobertoFerrara_ @imbimbo @giusvisc sharing science and frendship! Thank you for your great support! This is not just work and science, This part of our life ❤️

[أنس الشريف Anas Al-Sharif @AnasAlSharif0]

This is my will and my final message. If these words reach you, know that Israel has succeeded in killing me and silencing my voice. First, peace be upon you and Allah’s mercy and blessings.

Allah knows I gave every effort and all my strength to be a support and a voice for my people, ever since I opened my eyes to life in the alleys and streets of the Jabalia refugee camp. My hope was that Allah would extend my life so I could return with my family and loved ones to our original town of occupied Asqalan (Al-Majdal). But Allah’s will came first, and His decree is final. I have lived through pain in all its details, tasted suffering and loss many times, yet I never once hesitated to convey the truth as it is, without distortion or falsification—so that Allah may bear witness against those who stayed silent, those who accepted our killing, those who choked our breath, and whose hearts were unmoved by the scattered remains of our children and women, doing nothing to stop the massacre that our people have faced for more than a year and a half.

I entrust you with Palestine—the jewel in the crown of the Muslim world, the heartbeat of every free person in this world. I entrust you with its people, with its wronged and innocent children who never had the time to dream or live in safety and peace. Their pure bodies were crushed under thousands of tons of Israeli bombs and missiles, torn apart and scattered across the walls.

I urge you not to let chains silence you, nor borders restrain you. Be bridges toward the liberation of the land and its people, until the sun of dignity and freedom rises over our stolen homeland. I entrust you to take care of my family. I entrust you with my beloved daughter Sham, the light of my eyes, whom I never got the chance to watch grow up as I had dreamed.

I entrust you with my dear son Salah, whom I had wished to support and accompany through life until he grew strong enough to carry my burden and continue the mission.

I entrust you with my beloved mother, whose blessed prayers brought me to where I am, whose supplications were my fortress and whose light guided my path. I pray that Allah grants her strength and rewards her on my behalf with the best of rewards.

I also entrust you with my lifelong companion, my beloved wife, Umm Salah (Bayan), from whom the war separated me for many long days and months. Yet she remained faithful to our bond, steadfast as the trunk of an olive tree that does not bend—patient, trusting in Allah, and carrying the responsibility in my absence with all her strength and faith.

I urge you to stand by them, to be their support after Allah Almighty. If I die, I die steadfast upon my principles. I testify before Allah that I am content with His decree, certain of meeting Him, and assured that what is with Allah is better and everlasting.

O Allah, accept me among the martyrs, forgive my past and future sins, and make my blood a light that illuminates the path of freedom for my people and my family. Forgive me if I have fallen short, and pray for me with mercy, for I kept my promise and never changed or betrayed it.

Do not forget Gaza… And do not forget me in your sincere prayers for forgiveness and acceptance.

Anas Jamal Al-Sharif
06.04.2025

This is what our beloved Anas requested to be published upon his martyrdom.

[Massimo Di Maio @MassimoDiMaio75]

Just published in @BMJOncology the report of @AIOMtweet national conference about patient-reported outcomes in clinical trials and clinical practice.

A relevant step in the awareness and scientific debate about these topics.
Many thanks to all coauthors!

https://t.co/qL5UHcbj9X

[Roberto Ferrara @RobertoFerrara_]

Can we spare adj chemo in resected EGFR NSCLC? Probably no. Our Cochrane metanalysis shows no OS difference with 1st/2nd gen EGFR TKI vs adj chemo.
Relapses during the EGFR TKIs drug off time were higher compared to adj chemo (45% vs 30%). @cochranecollab
https://t.co/9ved6Ct8Rw

[giuseppe viscardi @giusvisc]

Out in @CochraneLibrary our metanalysis on adj EGFR TKIs for EGFRm NSCLC
https://t.co/vTSWAfPhVW

🆚 TKI vs pbo: DFS↑ (HR 0.41), recurrences ↑post-TKI
🆚 TKI vs CT: DFS↑ (HR 0.47), OS unclear

💡Role of adj CT
❓Optimal TKI duration

@RobertoFerrara_ @MOcchipintiMD

[arsela prelaj @PrelajArsela]

Proud to announce the creation of the European Interdisciplinary Society for AI in Cancer Research @ESAC_cancerAI is here to advance AI focus on the multidisciplinarity necessary to, effectively implement AI in Cancer Research stellar Steering Committee ! #AIinCancer @jnkath

[giuseppe viscardi @giusvisc]

@ScaltritiLab Campania, Napoli

[Jordi Remon @JordiRemon]

2024: Fortunately is difficult to merge all ttx for NSCLC 🫁 in 1 slide. Hwv, still pending:
✏️avoid “me too” approvals if prices not ⬇️
✏️ consol TKI for all and for lifetime?
✏️⬆️genotyping access & drug access
✏️➕ academic trials of de-escalating
✏️periop vs neoadj@OncoAlert

[Angelica Petrillo @AngelicaSSophie]

Young oncologists Campania Team 💫 at the @AIOMtweet games!
A thrilling challenge among Southern 🇮🇹 regions #AIOMgiovani.
Together we stand stronger! 💪🏻

@AIOM_Campania @giusvisc

[giuseppe viscardi @giusvisc]

Facing complexity in stage III NSCLC
One size doesn't fit for all: personalization, multimodality and multidisciplinarity are required
@MarcelloTiseo @AIOM_Campania @AIOMtweet

[Filippo Gallina @filippog92]

An example of how a strong and well-prepared multidisciplinary team can achieve incredible results!

[giuseppe viscardi @giusvisc]

69.3% five-year survival rate in stage IIIA NSCLC with perioperative chemo-immunotherapy is the new milestone
https://t.co/4jZ4ozXQs1

[giuseppe viscardi @giusvisc]

☑️ pCR (and MPR) as reliable predictors of EFS after neoadjuvant CT-ICI in NSCLC
➡️ Need for additional biomarkers to personalize post-operative strategy
@dmarinelli93
@filippogan @RobertoFerrara_
@AntonioNuccio01
https://t.co/Rf2Pr3yWOO

[Roberto Ferrara @RobertoFerrara_]

Perioperative not better than neoadjuvant ICI in both pCR and non-pCR NSCLC.
Postoperative ICI must be tailored in a curative setting to reduce potential tox and treatment burden. Data on MPR are coming. @AntonioNuccio01 @dmarinelli93 @giusvisc https://t.co/7oVNaYUQgs

[giuseppe viscardi @giusvisc]

"AI literacy" for next-generation oncologists

[arsela prelaj @PrelajArsela]

Excited to share our new perspective in #ESMORWD, "Oncology Education in the Age of Artificial Intelligence.
we advocate that AI literacy has become a relevant skill x oncologists
https://t.co/7k5MORGJQR thanks to the co-authors @gfscoazec @Dykex6 and my friend @jnkath @myESMO